相关实验视频

Updated: May 5, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

在功能单细胞方法的基础上理解恩扎胺耐药性

Changhui Xue¹, Hyun-Kyung Ko¹, Kasen Shi¹

¹Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.

|April 11, 2025

概括

一个小小的前列腺癌细胞亚群与低的雄激素受体 (AR) 表达驱动对恩扎胺治疗的耐药性. 这些低AR细胞被选择并通过治疗扩大,导致抵抗割的前列腺癌 (CRPC).

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

转移性前列腺癌 (PCa) 治疗依赖于抗雄激素或割疗法.
雄激素依赖PCa (ADPC) 常常会产生耐药性,发展为无法治愈的割耐药PCa (CRPC).
从ADPC中出现CRPC的机制在很大程度上仍然不清楚.

研究的目的:

为了研究ADPC细胞的转录异质性.
了解ADPC细胞对恩扎胺治疗的反应.
为了确定前列腺癌中疗法耐药性的机制.

主要方法:

在LNCaP细胞的单细胞RNA测序 (scRNA-Seq).
孤立的安德روج因受体低/负 (ARlow/-) 细胞亚群.
使用异种移植模型进行体外和体外功能测定.
在异种移植的单核RNA-Seq上.

主要成果:

一个小小的亚群 (~10%) 的LNCaP细胞表达低或没有雄激素受体 (ARlow/-).
ARlow/-细胞表现出与CRPC相关的独特的转录形状和途径.
ARlow/-细胞在体外和体内都表现出对酶胺的耐药性.
在体内为ARlow/-细胞和非选择的AR阳性 (AR+) 细胞选择的恩扎胺治疗.

结论:

一个克隆选择和扩张模型解释了PCa中的恩扎胺耐药性.
预先存在的ARlow/-亚群被选择并通过抗雄激素疗法扩展.
向ARlow/-细胞可能是克服治疗耐药性的策略.

关键词:

受体受体是受体的受体.反对割的抵抗力.酵素胺胺的使用方法前列腺癌是前列腺癌.一个单细胞RNA-Seqq.

更多相关视频

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...